Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Rating of “Buy” from Analysts

Definium Therapeutics, Inc. (NASDAQ:DFTX) has been assigned an average recommendation of “Buy” from the seventeen research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $49.2308.

A number of equities analysts recently weighed in on DFTX shares. Canaccord Genuity Group set a $58.00 price objective on shares of Definium Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Leerink Partners set a $52.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Piper Sandler restated an “overweight” rating and set a $48.00 price target (down from $49.00) on shares of Definium Therapeutics in a research note on Friday, May 8th. Wall Street Zen lowered Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Oppenheimer set a $60.00 price target on Definium Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 22nd.

Definium Therapeutics Trading Down 3.4%

Shares of DFTX stock opened at $42.80 on Tuesday. Definium Therapeutics has a 1-year low of $7.96 and a 1-year high of $49.20. The firm has a market cap of $4.27 billion, a PE ratio of -17.19 and a beta of 2.20. The company has a 50-day moving average of $31.86 and a two-hundred day moving average of $23.04. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, analysts predict that Definium Therapeutics will post -2.27 EPS for the current year.

Insider Transactions at Definium Therapeutics

In other Definium Therapeutics news, CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the sale, the chief executive officer directly owned 1,098,246 shares in the company, valued at $49,454,017.38. This represents a 2.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brandi Roberts sold 3,013 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the sale, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. This represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 48,096 shares of company stock worth $2,165,763 in the last 90 days. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. lifted its holdings in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after purchasing an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after purchasing an additional 3,020 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Definium Therapeutics during the 4th quarter worth approximately $117,000. FNY Investment Advisers LLC acquired a new position in shares of Definium Therapeutics during the 3rd quarter worth approximately $107,000. Finally, Caxton Associates LLP acquired a new position in shares of Definium Therapeutics during the 3rd quarter worth approximately $126,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.